Janssen Research & Development, Llc

This study tests an experimental drug called JNJ-95597528 to see if it can improve moderate to severe eczema (atopic dermatitis) better than a placebo. About 180 adults will receive either the drug or a placebo for 12 weeks. The main goal is to measure how many people get at leas…

This study tests a combination of two drugs, amivantamab and olomorasib, in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to find the best dose and see if the combo can shrink tumors or slow their growth. About 60 participants…

This study compares a new drug delivery system (TAR-210) to standard chemotherapy for people with a specific type of bladder cancer that hasn't invaded muscle. The treatment is placed directly into the bladder. About 641 participants will be randomly assigned to receive either TA…

This study tests how well the drug guselkumab improves symptoms of psoriatic arthritis, a condition causing joint pain and skin patches. Researchers will use ultrasound to measure joint inflammation in 200 adults over 24 weeks. The goal is to see if guselkumab can reduce swelling…

This study tests whether adding the drug amivantamab to standard chemotherapy and immunotherapy can help people with advanced head and neck cancer live longer or shrink their tumors. About 500 adults who have not yet been treated for their recurrent or metastatic cancer will take…

This study tests a new way to deliver the drug erdafitinib directly into the bladder using a special system called TAR-210. It is for people with bladder cancer that has not spread into the muscle layer or has spread into it. The goal is to find the best dose and see if it is saf…

This study tests two new drug combinations (Tal-P and Tal-Tec) against standard treatments for people with multiple myeloma that has returned or stopped responding after 1 to 4 prior therapies. About 795 participants will be randomly assigned to one of the combinations or a stand…

This study tests whether adding a new drug (teclistamab or talquetamab) to standard therapy can better control multiple myeloma in people who are newly diagnosed and cannot have a stem cell transplant. About 1,590 participants will be randomly assigned to one of three treatment g…

This study looks at different ways to give the drug ibrutinib to people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Some participants will also get another drug called venetoclax. The goal is to see if lowering the dose early or changing it based on…

This study tests whether nipocalimab can reduce lupus disease activity better than a placebo. About 600 adults with moderate to severe lupus will receive either the drug or a placebo for 52 weeks. The main goal is to see if more people on nipocalimab achieve a meaningful reductio…

This study tests a new drug (JNJ-79635322) combined with other medicines (daratumumab, lenalidomide, or pomalidomide) for people with multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective dose and to check for side effects. About 140 adults w…

This study tests a new shot form of the drug amivantamab for people with advanced lung cancer that has specific EGFR mutations. The goal is to see if the drug can shrink tumors and to check its safety. About 520 adults with non-small cell lung cancer that cannot be cured will tak…

This is the first study in people to test a new drug called JNJ-87562761. It aims to find a safe and effective dose for patients whose multiple myeloma has come back or is not responding to current treatments. The study will enroll about 80 people to check for side effects and se…

This study is testing a new oral medication called icotrokinra for adults and adolescents with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. The main goal is to see if the drug can safely bring the disease into remission and keep it under control ov…

This study tests if certain preventive treatments can reduce or prevent taste changes caused by the drug talquetamab in people with multiple myeloma. About 210 participants will be randomly assigned to different preventive strategies. The goal is to improve quality of life by min…